Literature DB >> 12960122

Serum levels of insulin-like growth factor I and risk of squamous intraepithelial lesions of the cervix.

Xifeng Wu1, Guillermo Tortolero-Luna, Hua Zhao, Deepali Phatak, Margaret R Spitz, Michele Follen.   

Abstract

Squamous intraepithelial lesions (SILs) are areas of precancerous growth in the cervix that can be indicative of future cervical cancer. Insulin-like growth factors (IGFs) and their binding proteins (IGFBPs) have been implicated in cancer development. Recent studies have demonstrated that elevated plasma IGF-I levels are associated with increased risk of prostate, lung, colon, and breast cancers. In this case-control study, we analyzed the relationship between serum levels of IGF-I and IGFBP-3, and SILs of the cervix. The case patients were comprised of 267 women treated at The University of Texas M. D. Anderson Cancer Center Colposcopy Clinic in Houston, Texas for abnormal Pap smears. The clinic serves minority and economically disadvantaged women referred from the County Health Department clinics of Harris County, Texas. The control subjects were 238 healthy women receiving family planning and screening services at two Harris County Health Department clinics. Case patients with either high-grade or low-grade SILs had significantly higher serum levels of IGF-I, IGFBP-3, and molar ratios of IGF-I:IGFBP-3 than the control subjects did. IGF-I levels in the highest quartile were associated with significantly higher risk of SILs compared with the lowest quartile, independent of IGFBP-3 levels. The odds ratio for the fourth quartile of IGF-I level, relative to the first quartile, was 8.54 (95% confidence interval, 4.15-17.60; P < 0.0001) after adjustment for age, ethnicity, smoking status, and IGFBP-3 level. There was a dose-response relationship between risk of SILs and the level of IGF-I: as the level of IGF-I increased, so did the risk of SILs. In addition, the serum level of IGFBP-3 was significantly higher in case patients than in control subjects. However, after adjustment for IGF-I, no relationship was evident between IGFBP-3 level and risk of SILs. Serum levels of IGF-I may be a useful biomarker for assessing risk of SIL development.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12960122

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  14 in total

1.  Plasma levels of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in women with cervical neoplasia.

Authors:  Si Won Lee; Soo Yoon Lee; Sa Ra Lee; Woong Ju; Seung Cheol Kim
Journal:  J Gynecol Oncol       Date:  2010-09-28       Impact factor: 4.401

2.  Longevity in untreated congenital growth hormone deficiency due to a homozygous mutation in the GHRH receptor gene.

Authors:  Manuel H Aguiar-Oliveira; Francielle T Oliveira; Rossana M C Pereira; Carla R P Oliveira; Amanda Blackford; Eugenia H O Valenca; Elenilde G Santos; Miburge B Gois-Junior; Rafael A Meneguz-Moreno; Vanessa P Araujo; Luis A Oliveira-Neto; Roque P Almeida; Mário A Santos; Natalia T Farias; Debora C R Silveira; Gabriel W Cabral; Flavia R Calazans; Juliane D Seabra; Tiago F Lopes; Endrigo O Rodrigues; Livia A Porto; Igor P Oliveira; Enaldo V Melo; Marco Martari; Roberto Salvatori
Journal:  J Clin Endocrinol Metab       Date:  2009-12-04       Impact factor: 5.958

3.  Differential impacts of insulin-like growth factor-binding protein-3 (IGFBP-3) in epithelial IGF-induced lung cancer development.

Authors:  Woo-Young Kim; Mi-Jung Kim; Hojin Moon; Ping Yuan; Jin-Soo Kim; Jong-Kyu Woo; Guangcheng Zhang; Young-Ah Suh; Lei Feng; Carmen Behrens; Carolyn S Van Pelt; Hyunseok Kang; J Jack Lee; Waun-Ki Hong; Ignacio I Wistuba; Ho-Young Lee
Journal:  Endocrinology       Date:  2011-03-29       Impact factor: 4.736

4.  Requirement for stromal estrogen receptor alpha in cervical neoplasia.

Authors:  Sang-Hyuk Chung; Myeong Kyun Shin; Kenneth S Korach; Paul F Lambert
Journal:  Horm Cancer       Date:  2012-10-13       Impact factor: 3.869

5.  Requirement for estrogen receptor alpha in a mouse model for human papillomavirus-associated cervical cancer.

Authors:  Sang-Hyuk Chung; Kerri Wiedmeyer; Anny Shai; Kenneth S Korach; Paul F Lambert
Journal:  Cancer Res       Date:  2008-12-01       Impact factor: 12.701

Review 6.  Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach.

Authors:  Rongshi Li; Alan Pourpak; Stephan W Morris
Journal:  J Med Chem       Date:  2009-08-27       Impact factor: 7.446

7.  Climacteric in untreated isolated growth hormone deficiency.

Authors:  Menilson Menezes; Roberto Salvatori; Carla R P Oliveira; Rossana M C Pereira; Anita H O Souza; Luciana M A Nobrega; Edla A C Cruz; Marcos Menezes; Erica O Alves; Manuel H Aguiar-Oliveira
Journal:  Menopause       Date:  2008 Jul-Aug       Impact factor: 2.953

8.  Requirement of estrogen receptor alpha DNA-binding domain for HPV oncogene-induced cervical carcinogenesis in mice.

Authors:  Jieun Son; Jung Wook Park; Paul F Lambert; Sang-Hyuk Chung
Journal:  Carcinogenesis       Date:  2013-10-22       Impact factor: 4.944

9.  Insulin-Like Growth Factor I Receptor (IGF-IR) Ligands and BMI in Squamous Intra-Epithelial Lesion (SIL) of Cervix.

Authors:  Praveen Sablania; Swaraj Batra; Alpana Saxena
Journal:  J Clin Diagn Res       Date:  2016-02-01

10.  Clinical implications of insulin-like growth factor 1 system in early-stage cervical cancer.

Authors:  Y-F Huang; M-R Shen; K-F Hsu; Y-M Cheng; C-Y Chou
Journal:  Br J Cancer       Date:  2008-09-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.